Late-stage clinical development in lower urogenital targets: Sexual dysfunction

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 2, 2006, Pages

  Azam, Usman ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical development; Female sexual dysfunction; Premature ejaculation; Sexual dysfunction

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; APOMORPHINE; CITALOPRAM; DAPOXETINE; LI 301; LIDOCAINE; LOCAL ANESTHETIC AGENT; MU OPIATE RECEPTOR AGONIST; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; NITRATE; NM 100061; PHOSPHODIESTERASE V INHIBITOR; PRILOCAINE; PROSTAGLANDIN E1; PSD 502; SEROTONIN 3 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; UK 390957; VARDENAFIL; VASODILATOR AGENT; VI 0162;

BURNING SENSATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FEMALE SEXUAL AROUSAL DISORDER; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MALE SEXUAL DYSFUNCTION; NAUSEA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RHINITIS; SIDE EFFECT; STRESS INCONTINENCE; TREATMENT OUTCOME; URETHRA DISEASE; VIRILIZATION; VISUAL DISORDER;

ALPROSTADIL; ANDROGENS; BENZYLAMINES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; EJACULATION; ERECTILE DYSFUNCTION; FEMALE; HUMANS; IMPOTENCE; MALE; NAPHTHALENES; PHOSPHODIESTERASE INHIBITORS; QUESTIONNAIRES; RECEPTORS, DOPAMINE D2; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 32544454031     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706638     Document Type: Conference Paper

References (71)

1. ABDO, C.H., OLIVIEIRA, W.M., MOREIRA, E.D. & FITTIPALDI, J.A. (2004). Prevalence of sexual dysfunctions and correlated conditions in a sample of Brazilian women - results of the Brazilian study on sexual behavior (BSSB). Int. J. Impot. Res., 16, 160-166.
2. AMERICAN PSYCHIATRIC ASSOCIATION (APA). (1994). DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
3. AMERICAN PSYCHIATRIC ASSOCIATION (APA). (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th edn. text revision. Washington, DC: American Psychiatric Press.
4. ALTHOF, S.E. (1998). Evidence based assessment of rapid ejaculation. Int. J. Impot. Res., 10 (Suppl 2), S74-S76; discussion S77-S79.
5. ALTHOF, S.E., LEVINE, S.B., CORTY, E.W., RISEN, C.B., STERN, E.B. & KURIT, D.M. (1995). A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J. Clin. Psychiatry, 56, 402-407.
6. ANDERSSON, K.E. & WAGNER, G. (1995). Physiology of penile erection. Physiol. Rev., 75, 191-236.
7. BANCROFT, J., LOFTUS, J. & LONG, J.S. (2003). Distress about sex: a national survey of women in heterosexual relationships. Arch. Sexual Behav., 32, 193-208.
8. BASSON, R., BERMAN, J., BURNETT, A., DEROGATIS, L., FERGUSON, D., FOURCROY, J., GOLDSTEIN, I., GRAZIOTTION, A., HEIMAN, J., LAAN, F., LEIBLUM, S., PADMA-NATHAN, H., ROSEN, R.C., SEGRAVES, K., SEGRAVES, R.T., SHABSIGH, R., SIPSKI, M., WAGNER, G. & WHIPPLE, B. (2000). Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol., 163, 888-893.
9. BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
10. BERMAN, J.R., BERMAN, L. & GOLDSTEIN, I. (1999). Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology, 54, 385-391.
11. BERMAN, J.R., BERMAN, L.A., TOLER, S.M., GILL, J. & HAUGHIE, S. (2003). Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J. Urol., 170 (Part 1), 2333-2338.
12. BRAUNSTEIN, S.J., NACHTIGALL, L., UTIAN, W., KATZ, M., MILLER, S., WALDBAUM, A., BOUCHARD, C., DERZKO, C., BUCH, A., RODENBERG, C., LUCAS, J. & DAVIS, S.J. (2005). Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. Clin. Endocrinol. Metab., 90, 5226-5233.
13. BURNETT, A.L. (1997). Nitric oxide in the penis: physiology and pathology. J. Urol., 157, 320-324.
14. COSTABILE, R., MCMURRAY, J.G., SINGH, G., WIATRAK, M. & PETERSON, C. (2005). Topical alprostadil for the treatment of premenopausal women with female sexual arousal disorder (FSAD); abstract no. 738. American Urological Association Annual Meeting, San Antonio, Texas, U.S.A.
15. DAMIS, M., PATEL, Y. & SIMPSON, G.M. (1999). Sildenafil in the treatment of SSRI-induced sexual dysfunction: a pilot study. Prim. Care Companion J. Clin. Psychiatry, 1, 184-187.
16. DE AMICIS, L.A., GOLDBERG, D.C., LOPICCOLO, J., FREIDMAN, J. & DAVIES, L. (1985). Clinical follow-up of couples treated for sexual dysfunction. Arch. Sex Behav., 14, 467-489.
17. DIAMOND, L.E., EARLE, D.C., ROSEN, R.C., WILLET, M.S. & MOLINOFF, P.B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impot. Res., 16, 51-59.
18. DRESSER, M., JAZRAWI, R.P., DESAI, D. & MODI, N.B. (2005). Dapoxetine for the treatment of premature ejaculation: lack of interaction with PDE5 inhibitors. J. Urol., 173 (Suppl), 201 (abstract 739).
19. FUGL-MEYER, K. & FUGL-MEYER, A.R. (2002). Sexual disabilities are not singularities. Int. J. Impot. Res., 14, 487-493.
20. GENGO, P.J., GUILIANO, F., McKENNA, K., CHESTER, A. & LOVENBURG, T. (2005). Monaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. J. Urol., 173 (Suppl), 201 (abstract 878).
21. GESSA, G.L. & TAGLIAMONTE, A. (1974). Possible role of brain serotonin and dopamine in controlling male sexual behaviour. Adv. Biochem. Psychopharmacol., 11, 217.
22. GOLDSTEIN, I., LUE, T.F., PADMA-NATHAN, H., ROSEN, R.C., STEERS, W.D. & WICKER, P.A. (1998). Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med., 338, 1397-1404.
23. GUAY, A.T. (2001). Decreased testosterone in regularly menstruating women with decreased libido: a clinical observation. J. Sex Marital Ther., 27, 515-519.
24. GUAY, A.T., MUNARRIZ, R. & SPARK, R. (2001). Serum androgen and androgen precursor hormone levels in women with and without sexual dysfunction (abstract). Yearly Meeting of the Female Sexual Function Forum, Boston, October 2001.
25. HIEMKE, C. & HARTTER, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther., 85, 11-28.
26. HIRSCH, M., DONATTUCI, C., GLINA, S., MONTAGUE, D., MONTORSI, F. & WYLLIE, M. (2004). Standards for clinical trials in male sexual dysfunction: erectile dysfunctions and rapid ejaculation. J. Sex Med., 1, 87-93.
27. JUDD, H.L. (1976). Hormone dynamics associated with the menopause. Clin. Obstet. Gynecol., 19, 775-799.
28. JUDD, H.L. & YEN, S.S.C. (1973). Serum androstenedione and testosterone levels during the menstrual cycle. J. Clin. Endocrinol. Metab., 36, 475-481.
29. KAPLAN, H.S. (1974). The New Sex Therapy: Active Treatment of Sexual Dysfunction. New York: Brunner/Maazel.
30. KARA, H., AYDIN, S., YUCEL, M., AGARGUN, M.Y., ODABAS, O. & YILMAZ, Y. (1996). The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J. Urol., 156, 1631-1632.
31. KELTNER, N.L., McAFEE, K.M. & TAYLOR, C.L. (2002). Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect. Psychiatr. Care, 38, 111-116.
32. KILIC, S., ERGIN, H. & BAYDINC, Y.C. (2005). Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. Int. J. Androl., 28, 47-52.
33. KIM, S.W. & PAICK, J.S. (1999). Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology, 54, 544-547.
34. LAAN, E., VAN LUNSEN, R.H., EVERAERD, W., RILEY, A., SCOTT, E. & BOOLELL, M. (2002). The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J. Womens Health Gender-Based Med., 11, 357-365.
35. LAUMANN, E.O., PAIK, A. & ROSEN, R.C. (1999a). Sexual dysfunction in the United States: prevalence and predictors. JAMA, 281, 537-544.
36. LAUMANN, E.O., PAIK, A. & ROSEN, R.C. (1999b). The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int. J. Impot. Res., 11 (Suppl 1), S60-S64.
37. MASTERS, W. & JOHNSON, V. (1970). Human Sexual Inadequacy. Boston, MA: Little, Brown.
38. MCMAHON, C.G. (1998). Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J. Urol., 159, 1935-1938.
39. MCMAHON, C.G. & TOUMA, K. (1999). Treatment of premature ejaculation with paroxetine hydrochloride. Int. J. Impot. Res., 11, 241-245.
40. MCMAHON, C.G. & SAMALI, R. (1999). Pharmacological treatment of premature ejaculation. Curr. Opin. Urol., 9, 553-561.
41. METZ, M.E., PRYOR, J.L., NESVACIL, L.J., ABUZZAHAB, F. & KOZNAR, J. (1997). Premature ejaculation: a psychophysiological review. J. Sex Marital Ther., 23, 3-23.
42. MOLINOFF, P.B., SHADIACK, A.M., EARLE, D., DIAMOND, L.E. & QUON, C.Y. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann. NY Acad. Sci., 994, 96-102.
43. MONTAGUE, D.K., JAROW, J. & BRODERICK, G.A. (2004). AUA guideline on the pharmacologic management of premature ejaculation. J. Urol., 172, 290-294.
44. MONTEJO-GONZALEZ, A.L., LLORCA, G., IZQUIERDO, J.A., LEDESMA, A., BOUSONO, M., CALCEDO, A., CARRASCO, J.L., CIUDAD, J., DANIEL, E., DE LA GANDARA, J., DERECHO, J., FRANCO, M., GOMEZ, M.J., MACIAS, J.A., MARTIN, T., PEREZ, V. & SANCHEZ, J.M. (1997). SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther., 23, 176-194.
45. PARK, K., MORELAND, R.B., GOLDSTEIN, I., ATALA, A. & TRAISH, A. (1998). Sildenafil inhibits phosphodiesterase 5 in human clitoral corpus cavernosum smooth muscle. Bioch. Biophys. Res. Commun., 248, 612-617.
46. PATRICK, D.L., ALTHOF, S.E., PRYOR, J.L., ROSEN, R., ROWLAND, D.L., HO, K.F., McNULTY, P., ROTHMAN, M. & JAMIESON, C. (2005). Premature ejaculation: an observational study of men and their partners. J. Sex Med., 2, 356-364.
47. PEROUTKA, S.J. & SNYDER, S.H. (1979). Multiple serotonin receptors: differential binding of (3H) 5-hydroxytryptamine, (3H) lysergic acid diethylamide and (3H) spiroperidol. Mol. Pharmacol., 16, 687-699.
48. PRYOR, J.L., ALTHOF, S.E., STEIDLE, C., MILOSLAVSKY, M. & KELL, S. (2005). Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. J. Urol., 173 (Suppl), 201, (abstract 740).
49. ROSEN, R., PORST, H. & MONTORSI, F. (2004a). The premature ejaculation prevalence and attitudes (PEPA) survey: a multi-national survey, [abstract]. 11th World Congress of the International Society of Sexual and Impotence Research, October 17-21.
50. ROSEN, R.C., CAPPELLERI, J.C. & GENDRANO III, N. (2002). The international index of Erectile Function (IIEF): a state of the art review. Int. J. Impot. Res., 14, 226-244.
51. ROSEN, R.C., DIAMOND, L.E., EARLE, D.C., SHADIACK, A.M. & MOLINOFF, P.B. (2004b). Evaluation of the safety, pharmacokinetics, and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. Int. J. Impot., 16, 135-142.
52. ROSEN, R.C., LANE, R.M. & MENZA, M. (1999). Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol., 19, 67-85.
53. ROWLAND, D.L., PERELMAN, M.A., ALTHOF, S., BARADA, J., McCULLOUGH, A., BULL, S., JAMIESON, C. & HO, K.F. (2004a). Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J. Sex. Med., 1, 225-232.
54. ROWLAND, D.L., TAI, W.L., BRUMMETT, K. & SLOB, A.K. (2004b). Predicting responsiveness to the treatment of rapid ejaculation with 25 mg clomipramine as needed. Int. J. Impot. Res., 16, 354-357.
55. SALONIA, A., MAGA, T., COLOMBO, R., SCATTONI, V., BRIGANTI, A., CESTARI, A., GUAZZONI, G., RIGATTI, P. & MONTORSI, F. (2002). A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J. Urol., 168, 2486-2489.
56. SCHARKO, A.M. (2004). Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. Am. J. Am. Acad. Child Adolesc. Psychiatry, 43, 1071-1079.
57. SHIFREN, J.L., BRAUNSTEIN, G.D., SIMON, J.A., CASSON, P.R., BUSTER, J.E., REDMOND, G.P., BURKI, R.E., GINSBURG, E.S., ROSEN, R.C., LEIBLUM, S.R., CARAMELLI, K.E. & MAZAR, N.A. (2000). Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med., 343, 682-688.
58. SYMONDS, T., ROBLIN, D., HART, K. & ALTHOF, S. (2003). How does premature ejaculation impact a man's life? J. Sex. Marital Ther., 29, 361-370.
59. TORK, I. (1990). Anatomy of the serotonergic system. Ann. NY Acad. Sci., 600, 6.
60. UECKERT, S., HEDLUND, P., BOGUN, Y., STEIF, C., JONAS, U., ANDERSSON, K.E. & OELKE, M. (2003). Immunohistochemical presence of cyclic AMP- and cyclic GMP-Phosphodiesterase isoenzymes in the human clitoris. Abstract no. 1208. American Urological Association Annual Meeting, Chicago, IL, U.S.A.
61. WALDINGER, M.D. (2002). The neurobiological approach to premature ejaculation. J. Urol., 168, 2359-2367.
62. WALDINGER, M.D. (2003). Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int. J. Impot. Res., 15, 309-313.
63. WALDINGER, M.D., HENGEVELD, M.W. & ZWINDERMAN, A.H. (1994). Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry, 151, 1377-1379.
64. WALDINGER, M.D., HENGEVELD, M.W., ZWINDERMAN, A.M. & OLIVIER, B. (1998a). An empirical operationalization study of DSM IV diagnostic criteria for premature ejaculation. Int. J. Psychiatry Clin. Pract., 2, 287-293.
65. WALDINGER, M.D., HENGEVELD, M.W., ZWlNDERMAN, A.M. & OLIVIER, B. (1998b). Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J. Clin. Psychopharmacol., 18, 274-281.
66. WALDINGER, M.D., QUINN, P., DILLEEN, M., MUNDAYAT, R., SCHWEITZER, D.H. & BOOLELL, M. (2005a). A multinational population survey of intravaginal ejaculatory latency time. J. Sex Med., 2, 492-497.
67. WALDINGER, M.D., ZWINDERMAN, A.H. & OLIVIER, B. (2001). Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J. Clin. Psychopharmacol., 21, 293-297.
68. WALDINGER, M.D., ZWINDERMAN, A.H. & OLIVIER, B. (2004). On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur. Urol., 46, 510-516.
69. WALDINGER, M.D., ZWINDERMAN, A.H., OLIVIER, B. & SCHWEITZER, D.H. (2005b). Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J. Sex Med., 2, 498-507.
70. WEBSTER, L.J. & MICHELAKIS, E.D. (2004). Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective placebo controlled, double-blind crossover trial. Arch. Int. Med., 164, 514-520.
71. WORLD HEALTH ORGANIZATION. (1992). International Statistical Classification of Diseases and Related Health Problems, Revision. Geneva: World Health Organization.